GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Samsung BioLogics Co Ltd (XKRX:207940) » Definitions » Total Premiums Earned

Samsung BioLogics Co (XKRX:207940) Total Premiums Earned


View and export this data going back to 2016. Start your Free Trial

What is Samsung BioLogics Co Total Premiums Earned?

Total Premiums Earned only applies to insurance companies.


Samsung BioLogics Co Business Description

Traded in Other Exchanges
N/A
Address
125, Cheomdan-daero, Yeonsu-gu, Incheon, KOR
Founded in 2011, Samsung Biologics is a South Korean contract development and manufacturing organization with a global client base. Europe and the US contribute 90% of its total revenue. It provides end-to-end development and manufacturing services from cell line developments to final commercial manufacturing. As of 2023, Samsung Biologics had a total production capacity of 604,000 liters, one of the largest in the world. Its CDMO services account for 72.4% of its total revenue. The balance comes from subsidiary Samsung Bioepis, acquired in 2022. Samsung Bioepis is involved in developing and manufacturing biosimilars.